Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01649778 · ClinicalTrials.gov registry record
Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced or Metastatic Renal Cell Carcinoma
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 662
- Enrollment target
NCT01649778: Completed study, sponsored by Novartis Pharmaceuticals.
NCT01649778 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 662 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01649778 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 662 participants
- Enrollment target
Study Summary
This is a global, multi-centre, long-term, prospective, observational study to evaluate treatment patterns and clinical outcomes in patients with advanced or metastatic RCC treated for the first time with pazopanib. The study is designed to enroll approximately 700-1000 patients in over the course of an enrollment period of approximately 18 months.There are no protocol-mandated visits or procedures associated with the study. Each patient is expected to participate for a maximum of 30 months or until premature discontinuation (i.e., due to death, withdrawal of consent, lost to follow-up or study termination).
Primary Outcome
To evaluate overall survival (OS), progression-free survival (PFS) and the overall response rate (ORR) in patients treated with pazopanib
Interventions
- DRUG Pazopanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 662 participants |
| Start Date | 2012-07-19 |
| Est. Completion | 2017-07-03 |
What the finished NCT01649778 record still lists
NCT01649778 is an observational study that tracks outcomes without assigning an intervention. The registered 662 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Pazopanib is the first listed.
NCT01649778 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01649778 about?
NCT01649778 is a clinical study titled "Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced or Metastatic Renal Cell Carcinoma". This is a global, multi-centre, long-term, prospective, observational study to evaluate treatment patterns and clinical outcomes in patients with advanced or metastatic RCC treated for the first time with pazopanib. The study is designed to enroll approximately 700-1000 patients in over the course o...
What is the current status of trial NCT01649778?
This trial is currently completed. The enrollment target is 662 participants. The study started on 2012-07-19. Estimated completion is 2017-07-03.
What interventions are being tested in trial NCT01649778?
The interventions under investigation include: Pazopanib (DRUG).
Who is sponsoring clinical trial NCT01649778?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05254743 · 662 participants · Phase 3
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- NCT07164443 · 663 participants · Phase 3
A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- NCT06607341 · 664 participants · NA
Community Engagement Alliance Against Disparities
- NCT01185132 · 660 participants · Phase 3
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI